Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Operating Leases: 2019-2025

Historic Operating Leases for Denali Therapeutics (DNLI) over the last 7 years, with Sep 2025 value amounting to $38.9 million.

  • Denali Therapeutics' Operating Leases fell 17.14% to $38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.9 million, marking a year-over-year decrease of 17.14%. This contributed to the annual value of $36.7 million for FY2024, which is 18.47% down from last year.
  • Latest data reveals that Denali Therapeutics reported Operating Leases of $38.9 million as of Q3 2025, which was down 5.20% from $41.0 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Operating Leases ranged from a high of $67.8 million in Q1 2021 and a low of $36.7 million during Q4 2024.
  • Moreover, its 3-year median value for Operating Leases was $46.9 million (2024), whereas its average is $47.0 million.
  • Data for Denali Therapeutics' Operating Leases shows a maximum YoY declined of 18.47% (in 2024) over the last 5 years.
  • Denali Therapeutics' Operating Leases (Quarterly) stood at $58.6 million in 2021, then fell by 9.43% to $53.0 million in 2022, then declined by 15.18% to $45.0 million in 2023, then decreased by 18.47% to $36.7 million in 2024, then decreased by 17.14% to $38.9 million in 2025.
  • Its last three reported values are $38.9 million in Q3 2025, $41.0 million for Q2 2025, and $43.0 million during Q1 2025.